Iron Deficiency Anemia Therapy Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Iron deficiency anemia remains the most prevalent blood disorder globally, affecting an estimated 1.2 billion people, with particularly high rates among women of reproductive age and children. The market encompasses both oral iron supplements, which dominate current usage due to lower cost, and IV iron therapies that are gaining traction for patients with severe deficiency or intolerance to oral treatments. With a 2025 valuation of $5.6 billion and projected 6.7% annual growth, the sector reflects both persistent unmet need and expanding treatment access in emerging economies.

• •IV iron segment is outpacing oral supplements due to better efficacy and faster hemoglobin correction
• •Rising prevalence linked to menstrual blood loss, gastrointestinal disorders, and bariatric surgery procedures
• •Healthcare infrastructure improvements in developing nations are expanding patient access to diagnosis and treatment

Aging demographics and increasing prevalence of chronic kidney disease are substantially expanding the patient pool requiring iron therapy. Growing clinical preference for IV iron among oncologists and gastroenterologists, driven by superior bioavailability and fewer gastrointestinal side effects compared to oral options, is shifting treatment patterns. Regulatory approvals of novel IV iron compounds with improved safety profiles are further accelerating adoption in developed markets.

• •Rising incidence of anemia in cancer patients undergoing chemotherapy fueling demand for IV formulations
• •Expanding indications for IV iron in non-dialysis chronic kidney disease patients
• •Increasing awareness campaigns by global health organizations improving screening and diagnosis rates

The market bifurcates into oral iron supplements, representing approximately 60% of current volume, and IV iron therapy, which commands higher per-patient revenue and faster growth momentum. Geographically, North America accounts for the largest market share due to favorable reimbursement policies and high healthcare spending, while Asia-Pacific is emerging as the fastest-growing region propelled by improving healthcare access in China and India.

• •Europe holds the second-largest share, driven by strong generic competition in oral iron and growing IV adoption in the UK and Germany
• •Latin America and Middle East/Africa represent smaller but expanding markets as economic development increases healthcare budgets
• •Ferric carboxymaltose and iron sucrose dominate the IV segment, while ferrous sulfate leads oral formulations

What are the recent trends and outlook?

The market is experiencing a paradigm shift toward IV iron as clinical evidence mounts regarding oral iron's limited efficacy in certain patient populations and gastrointestinal tolerability issues. Healthcare cost containment pressures are driving demand for lower-cost IV alternatives, potentially favoring manufacturers with efficient production capabilities. Long-term growth is expected to remain robust through 2035 as unmet need persists and next-generation iron complexes with enhanced targeting mechanisms advance through clinical trials.

• •Combination therapies pairing iron with erythropoiesis-stimulating agents gaining traction in chronic kidney disease management
• •Digital health integration and point-of-care testing improving early detection and treatment initiation
• •Patent expirations for blockbuster IV iron products will trigger significant pricing competition and market consolidation